期刊名称：PHARMACOGENOMICS & PERSONALIZED MEDICINE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and Scope
Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.
In particular, emphasis will be given to:
- Genomic and proteomic profiling
- Genetics and drug metabolism
- Targeted drug identification and discovery
- Optimizing drug selection & dosage based on patient's genetic profile
- Drug related morbidity & mortality intervention
- Advanced disease screening and targeted therapeutic intervention
- Genetic based vaccine development
- Patient satisfaction and preference
- Health economic evaluations
- Practical and organizational issues in the development and implementation of personalized medicine programs
The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews and evaluations, guidelines, policy papers, expert opinion and commentary, case reports and extended reports.
Pharmacogenomics and Personalized Medicine will no longer consider meta-analyses for publication.
Indexed online:
- Science Citation Index Expanded
- Journal Citation Reports/Science Edition
- Biological Abstracts
- BIOSIS Previews
- PubMed and PubMed Central (Pharmgenomics Pers Med)
- Embase, from 2009 (Correct as at December 8, 2016)
- Scopus, from 2009 (Correct as at December 8, 2016)
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
Instructions to Authors
Manuscript preparation
- While the editors fully understand the extra challenges posed to authors whose native language is not English, we must ask that all manuscripts be reviewed and edited by a native speaker of English with expertise in that area prior to submission
- Double-spacing
- 3-cm margins
- Page numbers
- Line numbers
- Clear concise language
- American spelling (all components of a manuscript must be in English)
- Ensure tables and figures are cited
- The preferred electronic format for text is Microsoft Word
- Manuscripts will be accepted in LaTeX as long as the native LaTeX and a PDF is also supplied
- Use International Systems of Units (SI) symbols and recognized abbreviations for units of measurement
- Do not punctuate abbreviations eg, et al, ie
- Spell out acronyms in the first instance in the abstract and paper
- Word counts are not specified. In general, shorter items range from 1000 to 3000 words and reviews from 3000 to 7,500
- Generic drug names are used in title, text, tables, and figures
- Suppliers of drugs, equipment, and other brand-name material are credited in parentheses (company, name, city, state, country)
- If molecular sequences are used, provide a statement that the data have been deposited in a publicly accessible database, eg, GenBank, and indicate the database accession number
- Depositing laboratory protocols on protocols.io is encouraged, where a DOI can be assigned to the protocol. To include a link to a protocol in your manuscript:
1) Describe your step-by-step protocol on protocols.io
2) Select "Get DOI" to issue your protocol with a unique DOI (digital object identifier)
3) Include the DOI link in the Methods section of your manuscript using the format provided by protocols.io: http://dx.doi.org/10.17504/protocols.io.xxxxxxx (where xxxxxxx is the unique DOI)
At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to consult your protocol when evaluating the manuscript. You can make your protocols public at any time by selecting "Publish" on the protocols.io website. Any referenced protocols will automatically be made public when your article is published.
Updated 7 January 2019
Editorial Board
Dr Bluth
Department of Pathology, Wayne State University, United States
Editor-in-Chief: Dr Martin H. Bluth
Dr. Bluth completed his MD and PhD (Immunology) degrees at SUNY Downstate Medical Center, residency in Clinical Pathology at Kings County Hospital, his fellowship training in Transfusion Medicine at the New York Blood Center and post-doctoral fellowship in tumor markers at the Veteran’s Affairs Medical Center in NY. He maintains board certification in his disciplines. He previously served as Chief Medical Officer for Consolidated Laboratory Management Systems, Vice President for BioMedica Corporation, Director of Pathology Laboratories for Michigan Surgical Hospital, Director of Research for SUNY Downstate Medical Center among other top tier positions and currently holds an appointment as Professor of Pathology at Wayne State University School of Medicine, Laboratory Director for Accutox Medical Diagnostic and National Medical Director for Kids Kicking Cancer. He also serves as Associate Editor for Henry’s Clinical Diagnosis and Management by Laboratory Methods, the premier textbook on Clinical Pathology and Laboratory Medicine, as Editor in Chief for four peer reviewed medical journals, and reviews for over a dozen other journals in various disciplines. He is a serial entrepreneur and founder of Bluth Bio Industries, LLC which provides consultation as well as facilitates and matures novel biomarkers, devices and therapeutics (www.bluthbio.com). Dr. Bluth is a leader in laboratory centric drug testing and pharmacovigilance guidance and serves on numerous committees including the Michigan State Medical Society Committee on Health Care Quality, Efficiency and Economics, and consults for numerous healthcare associations and political advocacy entities. Dr. Bluth is considered an expert in his field, has authored over 250 publications, and is sought after for speaking engagements and consultation worldwide.
Editorial Board
Hiltrud Brauch, Deputy Head, the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Professor Compton
UNITED STATES
Professor of Life Sciences, Arizona State University, Barrett Honors Faculty, Arizona State University, Affiliated Scholar, ASU Healthcare Delivery and Policy Program, Professor of Laboratory Medicine and Pathology, Mayo College of Medicine, Adjunct Professor of Pathology, Johns Hopkins Medical Institutions CMO, ASU Complex Adaptive Systems Institute, USA.
Dr Ellingrod
UNITED STATES
Vicki Ellingrod, Clinical Social and Administrative Sciences, College of Pharmacy and Medicine, University of Michigan, MI, USA
Takahisa Furuta, Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan
Professor Kearns
UNITED STATES
Gregory L. Kearns, PharmD, PhD, FCP, FAAP, President, Arkansas Children’s Research Institute; Senior Vice President and Chief Research Officer, Arkansas Children’s; Ross and Mary Whipple Family Distinguished Research Scientist; Professor of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Jing Li, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Qing Ma, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, NY, USA
Dr Maitland-van der Zee
NETHERLANDS
Anke-Hilse Maitland-van der Zee, Professor of Precision Medicine in Respiratory Diseases, Faculty of Medicine, University of Amsterdam, Netherlands.
Gene Morse, Professor, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, NY, USA
Wolfgang Sadee, Professor, Department of Cancer Biology and Genetics; Director, Center for Pharmacogenomics, The Ohio State University, USA; and Chief Scientific Officer, Aether Therapeutics Inc, USA.
Professor Somogyi
AUSTRALIA
Andrew Somogyi, Professor of Clinical and Experimental Pharmacology, Adelaide Medical School, University of Adelaide, Australia.
Professor Tainsky
UNITED STATES
Michael A. Tainsky, Professor, Department of Oncology, Fred and Barbara Erb Endowed Professor of Cancer Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
|
